Free Trial

BioStem Technologies Q4 2023 Earnings Report

$14.44 -0.98 (-6.36%)
(As of 12/20/2024 05:55 PM ET)

BioStem Technologies EPS Results

Actual EPS
-$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioStem Technologies Revenue Results

Actual Revenue
$11.44 million
Expected Revenue
$11.40 million
Beat/Miss
Beat by +$40.00 thousand
YoY Revenue Growth
N/A

BioStem Technologies Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioStem Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioStem Technologies and other key companies, straight to your email.

About BioStem Technologies

BioStem Technologies (OTCMKTS:BSEM), a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

View BioStem Technologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings